Get the Stockscreener App
4.00
13.04%
-0.60
Exozymes Inc stock is traded at $4.00, with a volume of 24,350.
It is down -13.04% in the last 24 hours and down -39.16% over the past month.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
See More
Previous Close:
$4.60
Open:
$4.6
24h Volume:
24,350
Relative Volume:
2.41
Market Cap:
$37.22M
Revenue:
$70,100
Net Income/Loss:
$-9.67M
P/E Ratio:
-3.4749
EPS:
-1.1511
Net Cash Flow:
$-7.09M
1W Performance:
-24.10%
1M Performance:
-39.16%
6M Performance:
-63.10%
1Y Performance:
-68.68%
1-Day Range:
$3.705
$4.881
1-Week Range:
$3.705
$5.41
52-Week Range:
$3.705
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
4.00 | 37.22M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exozymes Inc Stock (EXOZ) Latest News
Exozymes (EXOZ) grants VP 45,000 stock options - Stock Titan
EXOZ 424B FilingseXoZymes Inc. SEC 424B - Stock Titan
EXOZ 8-K FilingseXoZymes Inc. SEC 8-K - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
eXoZymes (EXOZ) Stock: Curia Deal Moves NCT Toward Commercial Production - Blockonomi
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com Nigeria
exozymes partners with Curia for NCT manufacturing scale-up - Investing.com
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com India
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com Canada
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com UK
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - The Joplin Globe
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com South Africa
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com UK
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com India
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com Canada
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com Australia
Exozymes CEO Michael Heltzen buys $6,405 in company stock - Investing.com
Exozymes (EXOZ) CEO adds stock with August buys and grant - Stock Titan
eXoZymes Inc. (EXOZ) Edges Lower, Holding Support at $6.13 After 0.77% DipNAAIM Exposure - dars.gov.et
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - Barchart.com
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - Barchart.com
eXoZymes Inc. (EXOZ) Holds Near $7.17 as Shares Trade Within Established RangePut Dominated - vinanet.vn
Primer: eXoZymes (EXOZ US)Aug 2026 - Smartkarma
Exozymes (EXOZ) CSO adds 32,964 shares from RSU vesting - Stock Titan
eXoZymes (EXOZ): Ends Up by 10.00% at $7.04; Trading Range: the Near-Term Reference Band Stretches From $6.69 to $7.39 in the Available RecordKey Reversal Day - vinanet.vn
eXoZymes Q2FY26 Results: Net loss widens to $2.88M, raises $6M - scanx.trade
eXoZymes Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance - Investing.com
Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance - Investing.com
EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization - TradingView
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - The Batesville Daily Guard
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - ACCESS Newswire
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - Newswire.com
eXoZymes (EXOZ): Ends Up by 10.00% at $7.04; Trading Range: the Near-Term Reference Band Stretches From $6.69 to $7.39 in the Available RecordBreakout Stock Alerts - dars.gov.et
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com Nigeria
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com India
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com South Africa
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com Canada
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - ACCESS Newswire
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - The Batesville Daily Guard
EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - marketscreener.com
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - Newswire.com
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - webull.com
eXoZymes Inc. (EXOZ) Drops 3% to $5.82, Pressuring Key Support at $5.53Narrow Range Breakout - vinanet.vn
eXoZymes Inc. (EXOZ) Drops 3% to $5.82, Pressuring Key Support at $5.53Hedge Fund Favorites - dars.gov.et
MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake - Stock Titan
EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
EXOZ 10-Q FilingseXoZymes Inc. SEC 10-Q - Stock Titan
Exozymes Inc Stock (EXOZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exozymes Inc Stock (EXOZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer |
Aug 25 '26 |
Buy |
7.51 |
350 |
2,630 |
14,203 |
| Korman Tyler Paz | Chief Scientific Officer |
Apr 09 '26 |
Sale |
10.53 |
750 |
7,894 |
729,123 |
| Korman Tyler Paz | Chief Scientific Officer |
Apr 08 '26 |
Sale |
10.04 |
750 |
7,530 |
729,873 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):